Obesity Throws Metabolism Timing Off Balance
April 23, 2025 / obesity metabolism timing / liver metabolic response / ATP AMP starvation / metabolic network disruption / University of Tokyo research
Obesity disrupts the precise timing of liver metabolic responses during starvation, despite intact molecular structures. This study highlights the importance of temporal coordination in metabolism and introduces a novel method for integrating time-series metabolic data.
Obesity changes how the gut responds to plant compounds, researchers report
April 28, 2025 / obesity gut microbiome / polyphenol metabolism obesity / rutin genistein gut health / BMI metabolic response / personalized nutrition microbiome
Obesity alters the gut’s metabolic response to polyphenols like rutin and genistein, reducing microbiome diversity and shifting metabolite profiles. These findings suggest BMI-specific effects on gut health and support the need for personalized nutrition approaches.
Investigating tirzepatide’s role in weight loss and metabolic health
April 24, 2025 / tirzepatide weight loss / GLP-1 fat oxidation / Zepbound metabolic adaptation / obesity drug mechanism / calorie intake reduction
Tirzepatide significantly reduces calorie intake and increases fat oxidation to promote weight loss, but does not prevent the usual metabolic slowdown during weight loss, underscoring its effectiveness and limitations in long-term obesity management.
Drug combination reduces breast cancer risk and improves metabolic health in rats
April 28, 2025 / bazedoxifene breast cancer / BZA CE metabolic health / tamoxifen alternative obesity / menopause cancer prevention / estrogen therapy breast fat
Bazedoxifene/conjugated estrogens (BZA/CE) reduced breast cancer risk factors and improved metabolic health in obese rats, suggesting a promising alternative to tamoxifen for high-risk, overweight women entering menopause.
A cross-sectional study investigating the L-shaped relationship between urinary albumin creatinine ratio and overweight/obesity in children and adolescents
April 26, 2024 / UACR obesity children / pediatric kidney health / albumin creatinine ratio study / NHANES obesity analysis / childhood BMI renal impact
A large NHANES-based study found a significant nonlinear inverse relationship between urinary albumin creatinine ratio (UACR) and obesity in U.S. children and adolescents, suggesting altered kidney function markers in overweight youth and underscoring the importance of early metabolic monitoring.
New $15 million study aims to understand cardiovascular and kidney disease risk factors in women
April 22, 2025 / women’s heart health / CKM syndrome research / cardiovascular risk factors women / kidney disease in women / American Heart Association study
A $15M American Heart Association study will investigate how cardiovascular-kidney-metabolic syndrome risk factors uniquely affect women, aiming to inform sex-specific prevention and treatment strategies across life stages like pregnancy and menopause.
Exploring the obesity paradox in chronic respiratory disease: the mediating effect of triglyceride-glucose index on mortality
April 26, 2025 / obesity paradox CRD / triglyceride-glucose index / BMI mortality risk / chronic respiratory disease survival / insulin resistance outcomes
This study reveals that higher BMI in chronic respiratory disease (CRD) patients is associated with lower non-cardiovascular mortality, potentially due to insulin resistance modulation via the triglyceride-glucose (TyG) index, offering insight into the obesity paradox.
Bellidifolin improves high-fat diet-induced obesity via gut microbiota and bile acid regulation, researchers discover
April 24, 2025 / bellidifolin obesity treatment / gut microbiota modulation / bile acid metabolism / Swertia diluta extract / high-fat diet intervention
Bellidifolin, derived from Swertia diluta, improves high-fat diet-induced obesity in mice by modulating gut microbiota and enhancing bile acid metabolism, reducing lipid accumulation, inflammation, and key markers of metabolic dysfunction.
ENDRA Life Sciences Deploys TAEUS Tech to Improve Metabolic Disease Detection
April 22, 2025 / TAEUS liver diagnostics / metabolic disease detection / steatotic liver disease screening / GLP-1 patient monitoring / noninvasive liver fat measurement
ENDRA Life Sciences is repurposing its TAEUS technology to enable point-of-care detection of liver fat and steatotic liver disease, supporting early diagnosis and monitoring of metabolic conditions in patients on GLP-1 therapies and related treatments.
MET gene mutations could be rare cause of MASLD, MASH
April 28, 2024 / MASLD genetic mutation / MET gene liver disease / MASH rare genetic cause / Mayo Clinic MET study / monogenic fatty liver
A Mayo Clinic study identified rare MET gene mutations as a monogenic cause of MASLD and MASH, offering new insights into disease mechanisms and potential for targeted therapies in patients lacking common metabolic risk factors.
Neurotensin promotes hepatic steatosis by regulating lipid uptake and mitochondrial adaptation in hepatocytes
April 27, 2025 / neurotensin liver steatosis / MASLD mitochondrial dysfunction / CD36 lipid uptake / PGC1α inhibition MASLD / NTS signaling fatty liver disease
Researchers found that neurotensin (NTS) promotes hepatic steatosis by increasing lipid uptake through CD36 and impairing mitochondrial lipid metabolism via PGC1α inhibition, highlighting NTS as a potential therapeutic target for MASLD and MASH.
Exosome-based combination therapy shows promise for treatment of metabolically challenging disease MASH
April 24, 2025 / exosome drug delivery / MASH combination therapy / FGF21 miRNA-223 treatment / metabolic liver disease therapy / exosome-based MASH treatment
Researchers engineered exosomes carrying FGF21 and miRNA-223 to target liver tissues, offering a promising combination therapy that addresses metabolic abnormalities, inflammation, and fibrosis in MASH, overcoming limitations of current treatments.
Doer Biologics Announces First Patient Dosed in Phase 2 Study of DR10624 for Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis
April 23, 2025 / MASLD treatment trial / MASH clinical study / DR10624 tri-agonist therapy / Doer Biologics liver disease / FGF21R GLP-1R GCGR agonist
Doer Biologics has dosed the first patient in a Phase 2 trial of DR10624, a first-in-class tri-agonist targeting FGF21R, GLP-1R, and GCGR, aiming to treat MASLD and MASH by improving liver fat, inflammation, and metabolic health.
Metabolic Syndrome in Midlife Linked to Higher Dementia Risk
April 24, 2025 / metabolic syndrome dementia / midlife dementia risk / young-onset dementia prevention / metabolic health brain aging / dementia risk lifestyle changes
A large South Korean study found that metabolic syndrome in midlife significantly increases the risk of young-onset dementia, especially among women and individuals in their 40s, emphasizing the importance of early lifestyle interventions for cognitive health.
Metabolic Syndrome Worsens Pain Catastrophizing in Psoriatic Arthritis
April 28, 2025 / psoriatic arthritis pain / metabolic syndrome psoriatic arthritis / pain catastrophizing PsA / metabolic health arthritis / PsA multidisciplinary treatment
A study found that metabolic syndrome significantly worsens pain catastrophizing in psoriatic arthritis patients, impacting psychological health and disease outcomes. Researchers emphasize the need for multidisciplinary interventions addressing both metabolic and emotional health in PsA management.
Prevalence of Metabolic Syndrome and Its Components in Patients With Major Depressive Disorder
April 27, 2025 / ‘metabolic syndrome / major depressive disorder / depression severity / triglycerides and depression / cardiovascular risk MDD / metabolic health screening / integrated psychiatric care
In treatment-naïve major depressive disorder (MDD) patients, metabolic syndrome (MetS) was highly prevalent (27.9%) and significantly correlated with depression severity. Age, triglyceride levels, and depression scores were independent predictors of MetS, emphasizing the need for integrated psychiatric-metabolic care.
Metabolic Score for Insulin Resistance Predicts Cardiovascular Risk in PsA
April 28, 2025 / psoriatic arthritis / METS-IR score / cardiovascular risk prediction / insulin resistance PsA / metabolic syndrome arthritis / PsA cardiovascular events / metabolic health biomarkers
A 10-year study found that a baseline METS-IR score above 2.48 significantly predicts cardiovascular risk in psoriatic arthritis (PsA) patients, independent of traditional risk factors like age, sex, hypertension, and smoking.
Interferon regulatory factor 8 identified as key driver of liver fat buildup in NAFLD
April 22, 2025 / NAFLD pathogenesis / IRF8 liver function / BMAL1 PPARγ axis / hepatic lipid metabolism / fatty liver disease therapy / IRF8 inhibition NAFLD / metabolic syndrome treatment
Researchers identified interferon regulatory factor 8 (IRF8) as a key promoter of liver fat buildup in NAFLD by activating the BMAL1-PPARγ axis, suggesting a new therapeutic target for treating hepatic steatosis and metabolic disorders.
Disruption of sterol biosynthesis by prescription drugs: A hidden threat to brain development
April 22, 2025 / sterol biosynthesis disruption / DHCR7 inhibition drugs / brain development risks / cholesterol synthesis and medication / psychiatric drugs brain impact / Smith-Lemli-Opitz Syndrome / developmental neurochemistry safety
Common prescription drugs can disrupt sterol biosynthesis by inhibiting DHCR7, posing hidden risks to brain development, especially during pregnancy; new research highlights urgent concerns over drug safety and developmental neurochemistry.